NEW OPPORTUNITIES TO TREAT COMBINED LUTS IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA -PREMISES AND ADVANTAGES


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This paper provides an overview of studies on the prevalence, pathogenesis and management of combined lower urinary tract symptoms (LUTs) in men. The authors emphasize the role of urodynamic studies in the diagnosis of LUTs in the pre- and postoperative period aimed at the early detection of functional lower urinary tract disorders and selection of the appropriate medical treatment.

Full Text

Restricted Access

About the authors

Z. K Gadzhieva

I.M. Sechenov First MSMU of Minzdrav of Russia

Email: zgadzhieva@ooorou.ru
Dr.Med.Sci. Moscow, Russia

Yu. B Kazilov

Research Institute of Uronephrology and Human Reproductive Health, I.M. Sechenov First MSMU of Minzdrav of Russia; Republican Urology Center

Email: dugurolog@mail.ru
Distance Learning PhD Student; Urologist Moscow, Russia; Makhachkala, Russia

References

  1. Кривобородов Г.Г., Мазо Е.Б. Гиперактивный мочевой пузырь. М.: Вече. 2003;392 с.
  2. Milsom I., Abrams P., Cardozo L., Roberts R.G., Thüroff J., Wein A.J. How wide-spread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87:760-766.
  3. Abrams P., Cardozo L., Fall M., Griffiths D., Rosier P., Ulmsten U., van Kerrebroeck P., Victor A., Wein A. The standartisation of terminology of lower urinary tract function: report from the Standartisation subcommittee of the International Continence Society. Neurourol. Urodyn. 2002;21:167-178.
  4. Chapple C.R., Roehrborn C.G. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol. 2006;49:651.
  5. Sexton C.C., Coyne K.S., Kopp Z.S., Irwin D.E., Milsom I., Aiyer L.P., Tubaro A., Chapple C.R., Wein A.J. The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int. 2009;103(3):12-23.
  6. Казилов Ю.Б., Гаджиева З.К., Мугутдинов Т.М., Казилов Б.Р. Распространенность различных нарушений мочеиспускания у жителей Республики Дагестан. Урология. 2016;4:42-47
  7. Restorick J.M., Mundy A.R. The Density of Cholinergic and Alpha and Beta Adrenergic Receptors in the Normal and Hyper-reflexic Human Detrusor. BJU Int. 1989;63(1):32-35.
  8. Lepor H. Pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. Rev in Urol. 2004;6(9):3-10.
  9. Blaivas J., Marks B., Weiss J., Panagoupolos G., Somaroo C. Differential diagnosis of overactive bladder in men. J Urol. 2009;182(6):2814-2817.
  10. Abrams P.H., Farrar D.J., Turner-Warwick R.T., Whiteside C.G., Feneley R.C. The results of prostatectomy: A symptomatic and urodynamic analysis of 152 patients. J Urol. 1979;121:640-642.
  11. Sibley G.N. The physiological response of the detrusor muscle to experimental bladder outflow obstruction in the pig. Br J Urol. 1987;60:332-336.
  12. Watson N., Chan Q., Bailon R. et al. Effects of aging on muscarinic receptors in the rat urinary bladder. FASEB J 1998, 12:A141.
  13. Mostwin J.L. Pathophysiology: the varieties of bladder overactivity. Urology. 2002;5(1):22-26.
  14. Лоран О.Б., Вишневский Е.Л., Вишневский А.Е. Лечение расстройств мочеиспускания у больных доброкачественной гиперплазией простаты адреноблокаторами. М.: ТЕРРА. 1998. 124 с
  15. Гаджиева З.К. Уродинамические исследования в диагностике и лечении нарушений мочеиспускания. Автореф. дис. док. мед. наук. М., 2009. 369 с
  16. Пытель Ю.А., Воркунов И.Я. Исследование функции почек у больных аденомой предстательной железы радиоизотопной ренографией. Урология и нефрология. 1965;6:11-18
  17. Abrams P. Detrusor instability and bladder outlet obstruction. Neurourol Urodyn. 1985;4:317.
  18. Thomas A.W., Abrams P. Lower urinary tract symptoms, benign prostatic obstruction and the overactive bladder. BJU International. 2000;85(Suppl. 3):57-68.
  19. Badhiwala N., Kuxhausen A., Vetter J. et al. Use of additional therapy for benign prostatic hyperplasia after TURP and laser vaporization. J Urol. 2015;193:93-94.
  20. Herrera-Munoz J.A. et al. Incidence of and factors associated with the use of medications and surgical retreatment after transurethral resection of the prostate. Rev Mex Urol. 2016;76(3):149-153.
  21. Montorsi F. Profile of silodosin. Eur Urol. 2010;4(9):491-495.
  22. Tatemichi S., Kobayashi K., Maezawa A., Kobayashi M., Yamazaki Y, Shibata N. α1-Adrenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213). Yakugaku Zasshi. 2006;126:209-216.
  23. Milani S., Djavan B. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest updated on a1-adrenoceptor antagonists. BJU Int. 2005;95(Suppl. 4):29-36.
  24. van Dijk M.M., de la Rosette J.J.M.C.H., Michel M.C. Tamsulosin - modified-release and oral-controlled absorption system formulation in the treatment of benign prostatic hyperplasia. Therapy. 2006; 3:237-246.
  25. Nickel J.C., Sander S., Moon T.D. Ameta-analysis of the vascular-related safety profi le and efficacy of a-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract. 2008;62: 1547-1559.
  26. Michel M.C., Vrydag W. α1-, α2- and β-Adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol. 2006;147:88-119.
  27. Andersson K.E. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol. Rev. 1993;45:253-308.
  28. Ohtake A., Ukai M., Hatanaka T., Kobayashi S., Ikeda K., Sato S., Miyata K., Sasamata M. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmacol. 2004;492(2-3):243-250.
  29. Wehling M., Burkhardt H., Kuhn-Thiel A., Pazan F., Throm C., Weiss C., Frohnhofen H. VALFORTA: a randomized trial to validate the FORTA (Fit fOR The Aged) classification. Age Ageing. 2016 Mar;45(2):262-67
  30. Chu F., Smith N., Uchida T. Efficacy and safety of solifenacin succinate
  31. mg once Daily: A multicenter, phase III, randomized, double blind, placebo-controlled, parallel-group trial in patients with overactive bladder. Curr Ther Res Clin Exp. 2009;70(6):405-420.
  32. Haab F., Cardozo L., Chapple C., Ridder A.M. for th Solifenacin Study Group: Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol. 2005;47(3):376-384.
  33. Chapple C., Ridder A.M. for the Solifenacin Study Group: Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol. 2005;47(3):376-384.
  34. Cardozo L. et al. Severity of overactive bladder symptoms and response to dose escalation in randomized, double-blind trial of solifenacin (SUNRISE). 2013 BJU International. poblished online http:// onlinelibrary.wiley.com/doi/10.1111/j.1464-410X.2012.11654.x/pdf
  35. Wesnes K.A., Edgar C., Tretter R.N., Bolodeoku J. Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. Expert Opin. Drug Saf. 2009;8(6):615-626.
  36. Wagg A., Compion G., Fahey A., Siddiqui E. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. 2012;110(11):1767-1774.
  37. Oelke M., Bachmann A., Descazeaud A., Emberton M., Gravas S., Michel M. C., N’dow J., Nordling J., de la Rosette J.J.; European Association of Urology. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013;64(1):118-140.
  38. Chapple Ch., Herschornb S., Abrams P., Sund F., Brodsky M., Guand Z. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with a-blockers. EAU. 2009;56:534-543.
  39. Тангриберганов М.Р. Особенности лечения доброкачественной гиперплазии предстательной железы в сочетании с клиническими симптомами гиперактивного мочевого пузыря. Автореф. дис. канд. мед. наук. М., 2012. 25 с
  40. Локшин К.Л., Тангриберганов М.Р., Гаджиева З.К. Современные возможности медикаментозной терапии при сохранении ирритативных симптомов после ТУР ДГПЖ. Эффективная фармакотерапия. Урология и Нефрология. 2012;1
  41. Гаджиева З.К., Казилов Ю.Б., Аляев Ю.Г., Абоян И.А. Особенности диагностики и лечения различных нарушений мочеиспускания врачами Республики Дагестан и других регионов Северо-Кавказского и Южного Федеральных округов. Урология. 2016;4:48-56
  42. Мазо Е.Б., Кривобородов Г.Г., Козырев С.В. Применение α-блокаторов и холинолитиков у больных доброкачественной гиперплазией простаты и гиперактивным мочевым пузырем. РМЖ. 2007;12:1016
  43. Saito T., Yamada H., Oshima et al. A comparative study of the efficacy and safety of tamsulosin hydrochloride alone and combination of propiverine hydrochloride and tamsulosin hydrochloride in the benign prostatic hypertrophy with pollakisuria and/or urinary incontinence. Jpn J Urol Surg. 1999;12:525-536.
  44. Athanasopoulos A., Gyftopoulos K., Giannitsas K., Fisfis J., Perimenis P., Barbalias G. Combination treatment with an α-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol. 2003;169:2253-2256.
  45. Lee K.S., Kim D. Y., Kim J.C. et al. Combination treatment with propiverine hydrochloride plus doxazosin gits in men with overactive bladder coexisting benign prostatic obstruction: a prospective, randomized, controlled, multicenter study. 2004 ICS annual meeting [abstract 207].
  46. Lee K.S., Choo M.S., Kim D.Y., Kim J.C., Kim H.J., Min K.S., Lee J.B, Jeong H.J., Lee T., Park W.H. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol. 2005;174:1334-1338.
  47. Kaplan S.A., Roehrborn C.G., Rovner E.S., Carlsson M., Bavendam T., Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006;296(19):2319-2328.
  48. Kaplan S.A., McCammon K., Fincher R., Fakhoury A., He W. Safety and tolerability of solifenacin add-on therapy to а-blocker treated men with residual urgency and frequency. J Urol. 2009;182:2825-2830.
  49. Yamaguchi O., Kakizaki H., Homma Y., Takeda M., Nishizawa O., Gotoh M., et al. Solifenacin as add-on therapy for overac ve bladder symptoms in men treated for lower urinary tract symp-toms-ASSIST, randomized controlled study. Urology. 2011;78(1):126-133.
  50. Berry S.J., Coey D.S., Walsh P.C., Ewing L.L. The develop-ment of human benign prostra c hyperplasia with age. J Urol. 1984;132(3):474-479.
  51. Касян Г.Р., Коновалов И.В. Современные возможности комбинированной терапии симптомов нижних мочевыводящих путей на фоне доброкачественной гиперплазии предстательной железы у мужчин. Исследования и практика в медицине. 2016;3(2):37-44
  52. Van Kerrebroeck P., Chapple C., Drogendijk T., Klaver M., Sokol R., Speakman M., et al; NEPTUNE Study Group. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol. 2013;64(16):1003-1012.
  53. Drake M.J., Chapple C., Sokol R., Oelke M., Traudtner K., Klaver M., et al. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension. Eur Urol. 2015;67 (2):262-270.
  54. Benner J.S., Nichol M.B., Rovner E.S., Jumadilova Z., Alvir J., Hussein M. et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 2010:105(9):1276-1282.
  55. Food and Drug Administration. Advisory Committee Briefing Document: Mirabegron (YM178) for the Treatment of Overactive Bladder, April 2012.
  56. Astellas Pharma Ltd. Betmiga™ (Mirabegron) SmPC, January 2013.
  57. Barkin J., Folia C. Emerging therapies: what’s new is old and what’s old is new. Can J Urol. 2012;19(Suppl. 1): 49-53.
  58. Takasu T., Ukai M., Sato S., Matsui T., Nagase I., Maruyama T. et al. Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl) amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther. 2007;321:642-1647.
  59. Tyagi P., Tyagi V., Chancellor M. Mirabegron: a safety review. Expert Opin Drug Saf. 2011;10(2):287-294.
  60. Chapple C., Yamaguchi O., Ridder A. et al. Clinical proof of concept study (Blossom) shows novel b3-adrenoceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder (abstract 674). Eur. Urol. 2008;7(3 Suppl.):239.
  61. Chapple C., Wyndaele J., van Kerrebroeck P. et al. Dose-ranging study of once-daily mirabegron (YM178), a novel selective 3-adrenoceptor agonist, in patients with overactive bladder (OAB). Eur. Urol. 2010;9(Suppl. 2):249.
  62. Nitti V., Herschorn S., Auerbach S. et al. The selective [beta] 3-adrenoreceptor agonist mirabegron is effective and well tolerated in patients with overactive bladder syndrome. J. Urol. 2011;185(4):e783-e784.
  63. Khullar V., Cambronero J., Angulo J. et al. Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder (OAB): post-hoc analysis of a prospective, randomised European-Australian phase III trial. Eur. Urol. 2012;11(1 Suppl.):e684-e684a.
  64. Chapple C., Kaplan S., Mitcheson D. et al. Randomised, double-blind, active-controlled phase III study to assess the long-term safety and efficacy of mirabegron in overactive bladder (OAB). Eur. Urol. 2012;11(1 Suppl.):e683-e683a.
  65. Chapple C.R., Kaplan S.A., Mitcheson D., Klecka J., Cummings J., Drogendijk T., Dorrepaal C., Martin N. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a ß(3)-adrenoceptor agonist, in overactive bladder. Eur. Urol. 2013;63(2):296-305.
  66. Khullar V., Amarenco G., Angulo J.C., Cambronero J., Haye K., Milsom I., Radziszewski P., Rechberger T., Boerrigter P., Drogendijk T., Wooning M., Chapple C. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur. Urol. 2013;63(2):283-295.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies